

Supplement 5

Interim Analysis

Table of Contents

5.1 Interim Analysis Report

5.2 Interim Efficacy Analysis Methods

Supplement 5.1: Interim Analysis Report

Interim Efficacy Analysis: Sealed Results (page 1 of 2)

Device: Vielight Rx Plus
Protocol version, date: 2.0, 19May20
Protocol title: A Randomized Study Evaluating the Efficacy of the Vielight Rx Plus in the Treatment of Covid-19 Respiratory Symptoms.
SAP date: 12Sep20
Interim analysis by: Mark Van Buskirk, Data Reduction LLC, 472 State Route 24, Chester, NJ 07930
Interim analysis date: 25Jan21

Sealed Results

Demography

Table 1 presents summary statistics and frequencies of demographic characteristics of Active and Control subjects. At baseline, 54.8% of patients were randomized to Active treatment and 45.2% to Control treatment. Mean age was 35.4 years (standard deviation (SD) 13.09, minimum 18, maximum 65 years). 64.4% of patients had symptom duration of 0-5 days and 35.6% of patients had symptom duration of 6-10 days. Mean response to question 1 at baseline (mean 4.6, SD 1.08) tended ($p=0.063$) to be greater in Active (mean 4.8, SD 0.80) than Control (mean 4.3, SD 1.31). Females were represented in 71.2% of patients and represented a statistically significant difference ($p=0.008$) in Active (85.0%) than Control (54.5%).

Time to Event

Table 2 provides Kaplan-Meier estimates at the interim based on 73 completed subjects. In a model stratified by symptom duration, the median time to complete resolution of WURSS question 1 symptoms (primary efficacy endpoint) was 15.5 days (95% confidence interval (CI) (10.0, 20.0) in Active and 18.0 days (95% CI 11.0, n/a) in Control, and the p -value by a stratified log-rank test was 0.104. Subgroup analysis by symptom duration categories indicated that the greatest difference in response between treatment groups was in those with symptoms 0-5 days with median time to complete resolution of symptoms 11.0 days for Active and 14.0 days for Control, which was marginally significant ($p=0.075$). In patients with symptoms 6-10 days, median time to event was 21 days in Active and 22 days in Control ($p=0.783$).

Table 3 presents results Cox proportional hazards models, stratified by duration of symptoms (0-5 days, 6-10 days). Baseline age, gender and race did not contribute to the regression model, and the primary statistical model for the interim efficacy analysis is stratified by symptom duration with factors for treatment and baseline Q1 covariate. Results indicated that the hazard ratio was 1.72 with 95% CI (0.967, 3.060) and p -value 0.065.

A data listing of demography and derived time-to-event is provided.

Interim Efficacy Analysis: Sealed Results (page 2 of 2)

Device: Vielight Rx Plus
Protocol version, date: 2.0, 19May20
Protocol title: A Randomized Study Evaluating the Efficacy of the Vielight Rx Plus in the Treatment of Covid-19 Respiratory Symptoms.
SAP date: 12Sep20
Interim analysis by: Mark Van Buskirk, Data Reduction LLC, 472 State Route 24, Chester, NJ 07930
Interim analysis date: 25Jan21

Interim Efficacy Analysis

At the interim efficacy analysis, the trial decision to stop the trial early for superiority was not met as the p-value for superiority by a symptom-duration stratified Cox model with baseline Q1 score covariate was $p=0.065$; and did not meet the established O'Brien Fleming¹ threshold for superiority of $p<0.0051$. The trial decision for futility was not met as the lower bound of the 95% CI for the hazard ratio (0.967) meets the criteria of conditional power $>50\%$ from Lan² equation 5.

Sample Size Re-Estimation

Sample size re-estimation by Cox regression utilizes the overall event rate (0.74) to update statistical power. Provided the event rate, protocol-stated hazard ratio (1.40) and sample size (280), the statistical power to detect a treatment difference is 68%. Power of 80% is achieved with 375 subjects. Under a fixed sample size condition of $n=280$ subjects, a hazard ratio of 1.58 is required to achieve 80% power to detect a treatment difference, given an overall event rate of 0.74.

¹ O'Brien PC and Fleming TR (1979). A multiple testing procedure for clinical trials. *Biometrics*. 35:549-556.

² Lan KKG and Simon R (1982). Stochastically curtailed tests in long-term clinical trials. *Communications in Statistics Series C*. 1:207-219.

Vivlight Bx Plus.
Protocol: Treatment of Covid-19 Respiratory Symptoms

Table 1
Interim Efficacy Analysis
Baseline Characteristics

Variable	Statistic	Category	Treatment Group		P-Value*
			Active (N= 40)	Control (N= 33)	
Age (years)	N		40	33	0.792
	Mean (SD)		35.0 (13.77)	35.8 (12.40)	
	Median (IQR) Min, Max		33.0 (23.5) (18.0, 65.0)	34.0 (23.0) (18.0, 65.0)	
Sex	N (%)	Female Male	34 (85.0) 6 (15.0)	18 (54.5) 15 (45.5)	0.008*
	N (%)	Caucasian Non-Caucasian	34 (85.0) 6 (15.0)	28 (84.8) 5 (15.2)	1.000
Symptom Days	N (%)	0-5 days 6-10 days	24 (60.0) 16 (40.0)	23 (69.7) 10 (30.3)	0.465
	N		40	33	0.312
Question 1 at Screening	Mean (SD)		5.0 (0.68)	4.9 (0.89)	
	Median (IQR)		5.0 (0.0)	5.0 (1.0)	
	Min, Max		(4.0, 6.0)	(4.0, 7.0)	
Question 1 at Baseline	N		40	33	0.063
	Mean (SD)		4.8 (0.80)	4.3 (1.31)	
	Median (IQR) Min, Max		5.0 (1.0) (3.0, 6.0)	4.0 (1.0) (1.0, 7.0)	
Randomization to 1st Treat Days	N		40	33	0.803
	Mean (SD)		0.5 (0.75)	0.5 (0.75)	
	Median (IQR) Min, Max		0.0 (1.0) (0.0, 3.0)	0.0 (1.0) (0.0, 2.0)	

* p-value for continuous variables by t-test and 2x2 categorical by Fisher's Exact test.

Vielicht Rx Plus.
 Protocol: Treatment of Covid-19 Respiratory Symptoms

Table 2
 Interim Efficacy Analysis
 Overall Time to Complete Resolution of MURSS Question 1 by Kaplan Meier Estimates

Model	Treatment	N		Censored	Median Days to Event Months 95% c.i.		LogRank P-Value Unstratified Stratified	
		Total	Failed		Months	95% c.i.	Unstratified	Stratified
Overall	Active	40	33	7	15.5	(10.0,20.0)	0.175	0.104
	Control	33	21	12	18.0	(11.0,)		
Symptom Days 0-5	Active	24	22	2	11.0	(8.0,18.0)	0.075	
	Control	23	15	8	14.0	(10.0,)		
Symptom Days 6-10	Active	16	11	5	21.0	(14.0,)	0.783	
	Control	10	6	4	22.0	(5.0,)		

Overall time (days) to resolution of respiratory symptoms (MURSS Q1) is from treatment start until the event or last follow-up if no event.
 Median and 95% confidence interval (c.i.) from Kaplan-Meier estimation in model stratified by symptom-days (0-6,6-10).25JAN21, T02_kn_interim

Vedlight Rx Plus.
 Protocol: Treatment of Covid-19 Respiratory Symptoms

Table 3
 Interim Efficacy Analysis
 Overall Time to Complete Resolution of WURSS Question 1 by Cox Proportional Hazards Model

Model	Parameter	Hazard Ratio	---95% Confidence Interval---	P-value
			Lower Upper	
1) Treatment Model	Treatment	1.5817	0.9055 2.7631	0.107
2) Treatment and Q1 Baseline Covariate	Treatment	1.7202	0.9670 3.0501	0.065
	Q1 Baseline	0.8084	0.6091 1.0729	0.141

Overall time (days) to resolution of respiratory symptoms (WURSS Q1) is from treatment start until the event or last follow-up if no event
 P-value by symptom duration stratified Cox proportional hazards model. Model 1 adjusted for baseline Q1. 25JAN21, 103_cox_interim

Supplement 5.2

Interim Efficacy Analysis Methods

Interim Efficacy Analysis

Device: Vielight Rx Plus
Protocol version, date: 2.0, 19May20
Protocol title: A Randomized Study Evaluating the Efficacy of the Vielight Rx Plus in the Treatment of Covid-19 Respiratory Symptoms.
SAP date: 12Sep20
Interim analysis by: Mark Van Buskirk, Data Reduction LLC, 472 State Route 24, Chester, NJ 07930
Interim analysis date: 26Sep20

Statistical Methods

The primary efficacy endpoint is defined as the time in days from date of first use of the device to the start date of improvement, defined as three consecutive days of reporting 0 on WURSS-44 question 1. The time to endpoint (days) is met (success) on the first of three consecutive days.

A single interim efficacy analysis was conducted on the primary efficacy endpoint in the first 73 subjects. The stopping boundary for superiority was defined as $p < 0.0051$ by O'Brien and Fleming¹ group-sequential testing design. The stopping boundary for futility is set at conditional power²

Results from the interim efficacy analysis are reported as 'unsealed' and 'sealed' results.

Unsealed results inform:

(1) Stop/Continue study decision:

Results communicated to the sponsor include the decision to either (a) stop the study for superiority, (b) stop the study for inferiority, or (c) continue the study until planned completion.

(2) Sample size re-estimation:

The statistical power of the study is addressed at the interim efficacy analysis. Statistical power analysis by Cox Proportional Hazards³ is performed using PASS software (NCSS Statistical Software, version 11.0). Sample size re-estimation uses the protocol specified hazard ratio of

¹ O'Brien PC and Fleming TR (1979). A multiple testing procedure for clinical trials. *Biometrics*. 35: 549-556.

² Lan KKG and Simon R (1982). Stochastically curtailed tests in long-term clinical trials. *Communications in Statistics Series C*. 1: 207-219.

³ Schoenfeld, David A. 1983. 'Sample-size formula for the proportional-hazards regression model', *Biometrics*, Volume 39, pages 499-503.

1.40 and sample size of 280 subjects and the observed event rate of 74% at the interim efficacy analysis.

Sealed results consist of treatment group comparisons of baseline characteristics, Kaplan-Meier time-to-event estimates, and hazard ratios and confidence intervals by Cox proportional hazards models. Statistical analysis of the primary efficacy endpoint is by Kaplan-Meier estimation, stratified by time since onset of symptoms (≤ 5 days, 6-10 days). Median days to improvement and 95% confidence

Interim Efficacy Analysis (page 2)

intervals are reported by treatment group. Separately by treatment group, the total number of subjects with the event (success of primary endpoint), without the event (censored), and total number of subjects are presented. For Kaplan-Meier estimation, the stratified test and univariate model by time of onset of symptoms are presented. The Cox proportional hazards model stratified by time since onset of symptoms was applied, and the hazard ratio and 95% confidence interval reported. Additionally, a stratified Cox model including covariate of baseline response to question 1 is reported.